Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Axsome Therapeutics in a research note issued on Monday, February 10th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($1.48) per share for the quarter. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $9.90 EPS.
A number of other research analysts have also issued reports on AXSM. Bank of America upped their price target on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research note on Tuesday. Needham & Company LLC restated a "buy" rating and set a $133.00 price target on shares of Axsome Therapeutics in a research note on Monday, February 10th. Leerink Partners upped their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, February 10th. HC Wainwright restated a "buy" rating and set a $190.00 price target on shares of Axsome Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $121.00 price target on shares of Axsome Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and an average target price of $147.13.
Read Our Latest Stock Report on AXSM
Axsome Therapeutics Stock Down 0.4 %
Shares of NASDAQ AXSM traded down $0.53 during trading hours on Wednesday, hitting $131.15. 1,064,118 shares of the stock were exchanged, compared to its average volume of 954,569. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company has a market cap of $6.36 billion, a PE ratio of -20.08 and a beta of 1.05. The firm has a fifty day moving average price of $97.84 and a 200-day moving average price of $93.27. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.18.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the business posted ($1.32) EPS.
Hedge Funds Weigh In On Axsome Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Assetmark Inc. acquired a new position in Axsome Therapeutics during the fourth quarter worth about $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the fourth quarter worth about $64,000. Aquatic Capital Management LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth about $76,000. KBC Group NV boosted its position in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after acquiring an additional 318 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.40% of the company's stock.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
